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INTRODUCTION
Several provocative tests have been designed to detect glaucoma in its
early stages(1-4). However, none of them have proved to be of clinical value.
In the past few years, studies with 2% ibopamine ophthalmic solution
have shown good ability to differentiate normal individuals from glaucoma
patients. Ibopamine (N-methyldopamine 3,4 di-isobutyrylester) 2% eye-
drops are hydrolyzed to epinine, a dopamine analogue. Epinine binds to α-
adrenergic and D-1 dopaminergic receptors. The adrenergic binding causes
a non-cycloplegic mydriasis, greater than 10% phenylephrine and 1% tropi-
camide(5), while the D-1 dopaminergic action causes an increase in aqueous
humor production(6-7). Because glaucoma patients may have an impaired
outflow system, a provocative test has been proposed based on the theory
Correlation between the ibopamine provocative test
and the diurnal tension curve in glaucoma patients
Purpose: To correlate the ibopamine provocative test with the diurnal
tension curve (highest intraocular pressure-IOP and range) in glaucoma.
Methods: This is a prospective case series including glaucoma patients
from the Federal University of Goiás, Glaucoma Service. Two 2% ibopamine
eyedrops were instilled into one or both eyes of each patient, 5 minutes
apart. Intraocular pressure was checked before and 30 and 45 minutes
after the second ibopamine instillation. Thereafter, the diurnal tension
curve of each patient was assessed with five independent measurements
(at every 2:30 hours), from 8:00 o’clock AM to 6:00 o’clock PM. Pearson’s
correlation coefficient was used to test the linear relation between the
intraocular pressure after the ibopamine instillation with the highest
intraocular pressure value and the intraocular pressure range in the
diurnal curve. Results: Thirty-one eyes from 22 patients were included.
There was a significant correlation between the intraocular pressure 30
and 45 minutes after ibopamine instillation and the highest intraocular
pressure assessed in the diurnal curve (r=0.356, p=0.04 and r=0.429,
p=0.01, respectively). However, no correlation between IOP after the use
of ibopamine and the diurnal intraocular pressure range at 30 (r=0.046,
p=0.8) and 45 minutes (r=0.109, p=0.5) was observed. Conclusion: The
ibopamine provocative test shows a significant correlation with the
highest intraocular pressure in the diurnal tension curve in glaucoma
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that glaucoma eyes would have a greater rise in intraocular
pressure (IOP) compared to normal individuals. Several
authors have achieved good sensitivity and specificity with
the ibopamine provocative test for glaucoma(7-11).
Glaucoma patients typically have larger intraocular pres-
sure fluctuations compared to the normal population(12-14).
Therefore, a single IOP measurement may not be able to detect
IOP peaks during the day. Patients apparently undergoing
progressive visual field loss were found to have significantly
more frequent IOP peaks than patients with stable visual
fields(15). Furthermore, large diurnal fluctuations are an inde-
pendent risk factor for glaucoma(16).
Because the diurnal curve demands the entire day to be
done, a simple test with good correlation with the IOP variabi-
lity (IOP range and IOP peak) during the day would be prefera-
ble. The purpose of this study is to correlate the ibopamine
provocative test with the diurnal tension curve in glaucoma.
METHODS
This is a prospective case series including glaucoma pa-
tients from the Federal University of Goiás, Glaucoma Service.
One or both eyes (if eligible) from each patient were consecu-
tively included after written and informed consent.
The inclusion criteria were: primary open-angle glaucoma,
(Goldmann applanation tonometry showing IOP ≥ 22 in at least
2 different examinations; gonioscopy showing an open angle;
a glaucomatous optic neuropathy, that is, localized or genera-
lized narrowing of the neuroretinal rim, disc hemorrhage, or
cup/disc asymmetry > 0.2 and at least two reliable(17) SITA
Standard Humphrey 24-2 abnormal visual fields.
The exclusion criteria included narrow angles, secondary
glaucoma, ocular hypertension or any significant change on
slit lamp examination that could interfere with the perimetric
examination (i.e: macular degeneration) or with the tonometry
(i.e: corneal opacity). We also excluded patients who under-
went refractive surgery, using prostaglandin analogues(8), re-
cent history (6 months) of ocular inflammation, functional
antiglaucomatous surgery (trabeculectomy, tube shunts), ina-
bility to perform any of the examination or refuse to participate
in the study. Patients using any antiglaucoma drug for less
than 3 months were also excluded.
Two 2% ibopamine eyedrops were instilled into one or
both eyes of each patient, 5 minutes apart. The IOP was
checked before, and 30 and 45 minutes after the second ibopa-
mine instillation, always around 9:00 o’clock AM. Thereafter,
the diurnal tension curve of each patient was assessed, at
least one week later (but no more than one month). Five
independent measurements were done (at every 2:30 hours),
from 8:00 o’clock AM to 6:00 o’clock PM.
The IOP was the mean of 2 independent and consecutive
measurements, always in the same calibrated Goldmann tono-
meter by the same examiner. A second person read the IOP. If
the difference between the first and the second measurements
was greater than 2 mmHg, a third measurement was made,
discarding the most discrepant value.
Statistical analysis was performed with SPSS (SPSS inc.,
Chicago, IL), version 11.5 software. The Komogorov-Smirnov
test was used to assess the normality of each distribution.
Pearson’s correlation coefficient was used to test the linear
relation between IOP after the ibopamine instillation with the
highest IOP value and the IOP range (difference between the
maximum and the minimum IOP recorded) in the diurnal curve.
Paired Student’s t test was used to analyze IOP variation
before and after ibopamine instillation. The measures of agree-
ment between the variables in the correlation was obtained
with the intraclass correlation coefficient. In our study, p<0.05
was considered statistically significant.
RESULTS
Thirty-one eyes from 22 patients were included in the
study. The mean age was 62.5 ± 10.9 years, and only 2 men (4
eyes) were included. IOP distribution is shown in Table 1. IOP
after 30 and 45 minutes after 2% ibopamine instillation was
significantly higher (p<0.001) than baseline IOP. However,
there was no noticeable difference between the IOP 30 and 45
minutes (p=0.09) after 2% ibopamine instillation. IOP peaks
were measured in the morning (8:00 o’clock AM or 10:30 AM)
in 93.5% of patients (29/31).
There was a significant correlation between the IOP 30 and
45 minutes (Figure 1) (r=0.356, p=0.04 and r=0.429, p=0.01,
respectively) and agreement (p=0.03 and p=0.01, respectively)
after ibopamine instillation and the highest IOP assessed in
the diurnal curve. However, there was no correlation between
IOP after the use of ibopamine and the diurnal IOP range at 30
(r=0.046, p=0.8) and 45 minutes (r=0.109, p=0.5).
DISCUSSION
Some studies have demonstrated the advantages of IOP
reduction in glaucoma patients(18-19), including normal tension
Table 1. Intraocular pressure distribution*
IOP at IOP at IOP at IOP rise IOP rise Highest IOP IOP fluctuation
baseline 30 min 45 min at 30 min at 45 min in the curve (higher–lower)
Mean 19.1 23.6 24.5 4.5 5.4 18.8 3.8
Standard deviation 04.1 04.1 03.9 5.1 3.7 02.8 1.8
* mmHg
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glaucoma(20). In the Advanced Glaucoma Intervention Study
(AGIS), almost no visual field deterioration was observed in
patients whose IOP was kept on safety and lower levels(18).
However, in a certain amount of patients, it is possible to have
glaucomatous progression despite apparently controlled IOP.
The visual field loss could have occurred at a time when IOP is
high, although it was controlled at the time of measurement. It
has been suggested that large diurnal fluctuations in IOP(12-14)
may be an additional risk factor in patients with glaucoma(16).
Furthermore, IOP peaks may not be recognized in a single
office IOP measurement and also be responsible for additional
visual field loss despite apparently controlled IOP(15).
Some authors(15) have shown that, in a population with a
30% prevalence of progressive loss of visual field, 75% of the
patients with peaks have progressive loss and 75% of those
without peaks do not have visual field progression. Another
group(16) has found that 29% of patients with a progressive
visual field loss had IOP peaks, compared with 5% of patients
with stable visual fields. In the same study, the IOP range was
also considered a strong and independent risk factor in pa-
tients with glaucoma. Therefore, the office IOP may not be
sufficient to assess the adequacy of treatment. Nevertheless,
the diurnal IOP assessment (diurnal tension curve) demands
the entire day to be done, what is somehow complicated in
busy clinics.
The 2% ibopamine eyedrops may be used as a provocative
test for glaucoma, being easy to perform, and has shown good
sensitivity/specificity results(8,11). It is reasonable to hypothe-
size that a linear association between the ibopamine test and
the IOP measurements from the diurnal curve (IOP peaks and
IOP range) would give us much more information than a single
IOP measurement. Additionally, ibopamine eyedrops cause a
non-cycloplegic mydriasis, allowing a comfortable fundus
examination for the patient. Furthermore, we would be asses-
sing the efficacy of the patient’s treatment during the day, and
not only at the time the patient is in the office. For that reason,
we decided to include glaucoma patients undergoing medical
treatment for glaucoma. However, it was necessary to exclude
patients using prostaglandin analogues that seem to reduce
the test’s sensitivity and the IOP rise(8). This fact limits the
test’s utility, since the prostaglandin analogues have become
the first (or second) line of treatment for the majority of glau-
coma specialists. It is possible that the increased aqueous
humor production by means of ibopamine instillation is also
drained through the uveo-scleral pathway(21).
The baseline IOP at 9:00 o’clock AM (19.1 ± 4.1 mmHg)
before the ibopamine test was slightly higher than the highest
IOP in the diurnal curve (18.8 ± 2.8 mmHg). However, the
diurnal IOP was assessed about 1 week after the ibopamine
provocative test with no change in the drug administration
and always using the same calibrated Goldmann tonometer by
the same masked examiner. In the present study, in 93.5% of
the patients (29/31), the IOP peak in the diurnal curve was
measured in the morning, close to the baseline IOP measure-
ment, before the ibopamine test. Therefore, we do not think
this is an inclusion bias, but only normal fluctuation in IOP
that may occur in glaucoma patients(12-14), since the highest
IOP during the day was almost coincident with the baseline
IOP. Another possible explanation is related to the D-1 dopa-
minergic ibopamine action(6), which may cause an overrespon-
se in aqueous humor production few minutes after the ibopa-
mine instillation that may fatigue the ciliary muscle receptors
for a period of time longer than a couple of weeks. We do not
believe that this is possible, since in a previous study, the IOP
in glaucoma patients dropped to values close to baseline
measurements only 180 minutes after ibopamine use(8).
In the present study, 2% ibopamine has demonstrated
good and similar ability to increase IOP in glaucoma patients,
at 30 and 45 minutes after instillation (p<0.001 at each time).
We decided to evaluate the IOP at both timepoints because
studies have shown good results with the ibopamine provoca-
tive test at 30(8) and 45 minutes(7,9) after ibopamine instillation.
In the earlier measurement, the cutoff point was set as greater
than 4 mmHg, while the IOP rise greater than 3 mmHg was used
at 45 minutes. We did not analyze the sensitivity and specifici-
ty because the performance of the test was not the purpose of
the present study.
The IOP after the ibopamine test was significantly correla-
ted with the highest IOP in the diurnal curve at 30 (r=0.356,
p=0.04) and 45 minutes (r=0.429, p=0.01). It means that, the
higher the IOP after the ibopamine eyedrops, the higher will be
the maximum IOP during the day (from 8:00 o’clock to 18:00
o’clock). Thus, it may be possible to associate high pressures
after the ibopamine test with IOP peaks during the day. On the
other hand, there was no significant correlation between the
ibopamine provocative test and the IOP range, at 30 (r=0.046,
p=0.8) and 45 minutes (r=0.109, p=0.5). It is possible that the
use of antiglaucomatous drugs could reduce the IOP range
during the day and consequently the correlation between the
ibopamine provocative test and the difference between the
Figure 1 - Scatterplot showing the relation between the highest IOP in
the diurnal curve and the IOP after ibopamine instillation
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highest and lowest IOP during the day. Patients off treatment
could have significant correlation between IOP range and
ibopamine test, and even better results testing its association
with peaks of IOP in the diurnal tension curve. Because IOP
fluctuation and peak within the 24 hours of the day may be
larger than that registered in the diurnal tension curve, our
results should be interpreted carefully. This is a limitation of
the study, and also another potential reason for our results,
that could be even better (or completely null) if the 24-hour
IOP was evaluated.
There are some interesting reports about the use of 2%
ibopamine eyedrops as an adjunctive test for glaucoma, with
good sensitivity/specificity results to differentiate normal in-
dividuals from glaucoma patients(7-9). Additionally, the non-
cycloplegic and large mydriasis(5) allows comfortable fundus
examination. We are now suggesting a new application for the
ibopamine test by correlating IOP after the test with the hi-
ghest IOP in the diurnal tension curve. Further studies confir-
ming our results and other potential uses for the ibopamine
test in glaucoma are suggested.
CONCLUSION
The ibopamine provocative test has a significant correla-
tion with the highest IOP in the diurnal tension curve in
glaucoma patients. However, no correlation was observed
with the IOP range.
RESUMO
Objetivo: Correlacionar o teste provocativo da ibopamina com
a curva diurna de pressão intra-ocular (Pio máxima e flutuação
da mesma) em pacientes com glaucoma. Métodos: Estudo
prospectivo incluindo pacientes com glaucoma provenientes
do CEROF-UFG. Duas gotas de ibopamina a 2% foram instila-
das em um ou ambos os olhos dos pacientes com intervalo de
5 minutos entre elas. A pressão intra-ocular foi checada antes,
30 e 45 minutos após a segunda gota de ibopamina. Após, a
curva diurna de pressão intra-ocular foi realizada com 5 medi-
das independentes (a cada 2:30 horas) entre 8:00 e 18:00 horas.
A correlação de Pearson foi utilizada para se testar a relação
linear entre a pressão intra-ocular após o uso da ibopamina, a
pressão intra-ocular máxima e a flutuação diurna da pressão
intra-ocular. Resultados: Trinta e um olhos de 22 pacientes
foram incluídos. Notou-se correlação estatisticamente signifi-
cativa entre a Pio 30 e 45 minutos após a instilação da ibopami-
na e a máxima pressão intra-ocular obtida na curva diurna
(r=0,356, p=0,04 e r=0,429, p=0,01, respectivamente). Entretan-
to, não foi observada correlação positiva com a flutuação
diurna da pressão intra-ocular aos 30 (r=0,046, p=0,8) e 45
minutos (r=0,109, p=0,5). Conclusão: O teste provocativo da
ibopamina apresentou alta correlação com a pressão intra-
ocular máxima na curva diurna em pacientes com glaucoma.
Entretanto, não foi notado relação linear direta com a flutua-
ção diurna da pressão intra-ocular.
Descritores: Glaucoma; Soluções oftálmicas; Pressão intra-
ocular; Agonistas de dopamina/uso diagnóstico; Ritmo circa-
diano; Estudo comparativo
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